Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $39.00 Average Target Price from Brokerages

Akero Therapeutics, Inc. (NASDAQ:AKRO) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $37.71.

AKRO has been the subject of several recent research reports. Bank of America began coverage on shares of Akero Therapeutics in a research report on Monday. They issued a “neutral” rating and a $30.00 price target for the company. HC Wainwright increased their price target on Akero Therapeutics from $40.00 to $43.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, UBS Group raised their target price on Akero Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th.

Akero Therapeutics Trading Up 0.1 %

Shares of AKRO stock opened at $20.79 on Friday. The stock’s fifty day moving average price is $24.75 and its two-hundred day moving average price is $21.19. The company has a market cap of $1.44 billion, a PE ratio of -7.29 and a beta of -0.38. The company has a debt-to-equity ratio of 0.05, a quick ratio of 29.27 and a current ratio of 29.27. Akero Therapeutics has a fifty-two week low of $11.25 and a fifty-two week high of $58.38.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Thursday, February 29th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.17). Equities analysts predict that Akero Therapeutics will post -4.06 EPS for the current fiscal year.

Insider Buying and Selling at Akero Therapeutics

In other Akero Therapeutics news, CEO Andrew Cheng sold 75,000 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $32.87, for a total value of $2,465,250.00. Following the transaction, the chief executive officer now owns 591,416 shares of the company’s stock, valued at $19,439,843.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Akero Therapeutics news, CEO Andrew Cheng sold 75,000 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $32.87, for a total value of $2,465,250.00. Following the sale, the chief executive officer now directly owns 591,416 shares in the company, valued at $19,439,843.92. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Jonathan Young sold 5,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $24.38, for a total transaction of $121,900.00. Following the sale, the chief operating officer now directly owns 263,306 shares in the company, valued at $6,419,400.28. The disclosure for this sale can be found here. In the last three months, insiders have sold 100,646 shares of company stock worth $3,319,877. Corporate insiders own 9.69% of the company’s stock.

Institutional Trading of Akero Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Orion Capital Management LLC purchased a new position in Akero Therapeutics during the third quarter worth about $51,000. Headlands Technologies LLC purchased a new stake in shares of Akero Therapeutics in the 4th quarter valued at about $28,000. Quarry LP lifted its position in Akero Therapeutics by 40.0% during the fourth quarter. Quarry LP now owns 1,750 shares of the company’s stock valued at $41,000 after purchasing an additional 500 shares during the last quarter. Strs Ohio grew its position in Akero Therapeutics by 100.0% in the fourth quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $46,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Quest Partners LLC bought a new position in shares of Akero Therapeutics during the 4th quarter valued at about $75,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.